When, if ever, would you re-challenge with immunotherapy for patients with metastatic RCC?

Checkpoint inhibitors combinations (IO/IO and TKI/IO) are the most likely way for a patient to experience a durable response. However, we need better treatment options for patients who are experiencing disease progression to these therapies. A number of new immune treatments are currently in clinica...